ArticleTranslational cancer research2026
Utidelone exhibits favorable responses in refractory patients with advanced breast cancer.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Utidelone plus capecitabine has brought therapeutic and survival benefits in the second-line treatment of patients with advanced breast cancer (ABC). However, its efficacy in the subsequent treatment remains to be disclosed. Our study aimed to investigate the efficacy and safety of utidelone in the treatment of refractory ABC in real-world. Methods: In this single-center, retrospective cohort study, clinical data were retrospectively collected from patients who received utidelone at Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen after developing resistance to anthracyclines or taxanes. The median progression-free survival (PFS) was estimated using the Kaplan-Meier method, and statistical analysis was performed using SPSS 18.0 software (IBM SPSS, Armonk, NY, USA). Results: A total of 20 patients were included in the study, 95% of whom had previously received third-line therapy or more at the time of utidelone treatment. The overall objective response rate (ORR) and disease control rate (DCR) were 15% and 80%, respectively, with a median PFS of 4.7 months [95% confidence interval (CI): 2.98-6.42]. Patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR Conclusions: Utidelone demonstrates favorable efficacy and safety in patients with refractory ABC, particularly in HR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.